ubrogepant
Trade name: Ubrelvy
Approved
Dec 23, 2019
Ubrogepant, a small molecule drug, is being developed by Merck & Co for the treatment of migraine. The calcitonin gene-related peptide receptor (CGRP) antagonist is administered orally as a film coated tablet. Ubrogepant is a competitive antagonist with high affinity, potency, and selectivity for the human CGRP receptor. In the four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002) ubrogepant demonstrated efficacy, safety and tolerability in the acute treatment of migraine among a broad patient population, including those who had an insufficient response to a triptan or those patients in whom triptans were contraindicated, as well as in patients who had moderate to severe CV risk profile. — NCATS
Clinical trial activity
17 trials · 6 clinical orgs · 3 marketing orgs
Earliest trial started Jul 1, 2012 (NCT01613248)
Timeline
2010s
2020s
- May 28, 2025
Aurobindo Pharma — Marketing Organization
Indications
Approved for
Mechanism of action
CALCRL antagonist
Approval history
- approvedDec 23, 2019
Chemistry & pharmacology
SMILES
C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC5=NC=CC=C45)C(=O)N1CC(F)(F)F)C6=CC=CC=C6- Mol. weight
- 549.5436 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaUbrogepant ↗
- NCATSAD0O8X2QJR ↗
- ChEMBLCHEMBL2364638 ↗
Also known as
- 1',2',5,7-tetrahydro-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-, (6s)- spiro(6h-cyclopenta(b)pyridine-6,3'-(3h)pyrrolo(2,3-b)pyridine)-3-carboxamide
- mk-1602
- mk-1602
- mk-1602
- mk-1602
- ubrogepant
- ubrogepant
- ubrogepant
- ubrogepant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06578585 | Phase 1 | Sep 13, 2024 | Lundbeck |
| NCT06417775 | Phase 3 | Sep 10, 2024 | AbbVie |
| NCT05892757 | Phase 1 | Jul 11, 2023 | AbbVie |
| NCT05503082 | Phase 4 | Aug 31, 2022 | AbbVie, Chicago Headache Center |
| NCT05214001 | Phase 4 | Jun 30, 2022 | University of Copenhagen |
| NCT05654298 | N/A | Mar 15, 2022 | Katholieke Universiteit Leuven |
| NCT05264129 | Phase 4 | Mar 7, 2022 | AbbVie |
| NCT05127954 | Phase 3 | Nov 12, 2021 | Allergan |
| NCT05125302 | Phase 3 | Nov 9, 2021 | Allergan |
| NCT04818515 | Phase 1 | Mar 17, 2021 | Allergan |
| NCT04492020 | Phase 3 | Aug 21, 2020 | Allergan |
| NCT04179474 | Phase 1 | Sep 26, 2019 | Allergan |
| NCT02873221 | Phase 3 | Sep 13, 2016 | Allergan |
| NCT02867709 | Phase 3 | Aug 26, 2016 | Allergan |
| NCT02828020 | Phase 3 | Jul 22, 2016 | Allergan |
| NCT01657370 | Phase 2 | Aug 1, 2012 | Allergan |
| NCT01613248 | Phase 2 | Jul 1, 2012 | Allergan |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 10 | 10 | 3 | 2012 |
| AbbVie | For profit | 4 | 3 | 3 | 2022 |
| Chicago Headache Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Lundbeck | For profit | 1 | 1 | 1 | 2024 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2022 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | MKTG | Dec 23, 2019 |
| AbbVie | For profit | NDA2 | Dec 23, 2019 |
| Allergan | For profit | MKTG | Dec 23, 2019 |
| Allergan | For profit | NDA | Dec 23, 2019 |
| Aurobindo Pharma | For profit | MKTG | May 28, 2025 |